PWAC
NBIX icon

Private Wealth Advisors (California)’s Neurocrine Biosciences NBIX Stock Holding History

Private Wealth Advisors (California)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,000
Closed -$244K – 69
2020
Q2 		$244K Buy
+2,000
New +$221K 0.17% 43

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Private Wealth Advisors (California)'s NBIX Position: Q3 2020 in Review

Private Wealth Advisors (California) sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 2,000 shares — an estimated $244K sold.

Private Wealth Advisors (California) first reported a position in NBIX in Q2 2020 and held it in 1 quarter. The position peaked at $244K in Q2 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Private Wealth Advisors (California) reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Private Wealth Advisors (California) sold 2,000 Neurocrine Biosciences shares in Q3 2020, an estimated $244K.
  • Private Wealth Advisors (California) first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 1 quarter.
  • Private Wealth Advisors (California)'s Neurocrine Biosciences position peaked at $244K in Q2 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Private Wealth Advisors (California)'s 13F filing for Q3 2020, filed 16 Nov 2020.